Advancing Bacteriophage for the Treatment of Bacterial Infections

AmpliPhi BioSciences Corporation is advancing the fight against antibiotic resistance through the development of innovative antibacterial solutions. We invite you to learn more about our proprietary bacteriophage technology and the promise it holds for combating critical health issues facing society.

Antibiotic resistance is one of the most pressing health issues facing the world today. Increasing antibiotic resistance levels are creating an environment in which even commonplace infections could again cause high mortality rates as was the case before the advent of widespread antibiotic usage.

Harnessing Viruses in theWar Against Disease

AmpliPhi seeks to employ the power of highly specific bacteriophages to fight infection. The Company’s proprietary approach utilizes bacteriophages, naturally occurring viruses that target and destroy infecting bacteria.

Lead Therapeutic Programs Targeting Major Unmet Medical Needs in Infectious Disease

Our lead programs include AmpliPhage-001 for the treatment of P. aeruginosa lung infections in CF patients and AmpliPhage-002 for the treatment of methicillin-resistant S. aureus (MRSA) infections.

Advancing Bacteriophage for the Treatment of Bacterial Infections

AmpliPhi BioSciences Corporation is advancing the fight against antibiotic resistance through the development of innovative antibacterial solutions. We invite you to learn more about our proprietary bacteriophage technology and the promise it holds for combating critical health issues facing society.

AmpliPhi -the global leader in developing phage therapy for treating infectious disease.

AmpliPhi Biosciences is a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics. Our proprietary pipeline is based on the use of bacteriophages, a family of viruses that infect only bacteria.

Latest News

January 6th 2015

AmpliPhi Provides Shareholder Update

More

December 31st 2014

AmpliPhi Biosciences to Host Shareholder Update Conference Call

More

Events and Presentations

  • March 8-11, 2015, ROTH Conference, Dana Point, CA
  • April 25 – 28, 2015, European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark
  • May 13 – 16, 2015, American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting, New Orleans, LA
  • May 30 – June 2, 2015, American Society of Microbiology (ASM) 115th General Meeting, New Orleans, LA
  • June 10 – 13, 2015 European Cystic Fibrosis Conference (ECFS), Brussels, Belgum
  • June 15 – 18, 2015, BIO International Convention, Philadelphia, PA


Latest Presentation

DateTitle
Q1 2015 APHB Non con Investor Deck

Investors

View our Investors Relations area.

More

 

Subscribe